Advertisement

Medical and Endocrine Therapy of the Infertile Male

  • Rebecca Z. Sokol

Abstract

The differential diagnosis of male factor infertility can be subdivided into four major diagnostic categories: (1) irreversible germ cell failure, (2) hypogonadotropic hypogonadism, (3) anatomic defects, and (4) idiopathic infertility. Therapies for germ cell failure and hypogonadotropic hypogonadism are clearly delineated. Anatomic defects are surgically corrected. A specific therapy for idiopathic infertility has yet to be defined, but a number of medical therapies have been proposed for its treatment. Because of the heterogeneity of the disorders that fall into this category, specific etiologic factors for each are not yet defined, which prevents identification of specific therapies. No single empiric medical therapy proposed has proven efficacious when studied in a controlled, prospective fashion. Placebo-controlled trials are necessary because the treatment-independent pregnancy rate is 30% in 1 year.1 A 30% improvement in pregnancy rate in a noncontrolled study is therefore meaningless.

Keywords

Luteinizing Hormone Hypogonadotropic Hypogonadism Testosterone Enanthate Testosterone Undecanoate Antisperm Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Glazner CMA, Kelly NJ, Weir MJA, et al. The diagnosis of male infertility: Prospective time-specific study of conception rates related to seminal analysis and post coital sperm-mucus, penetration and survival in otherwise unexplained infertility. Hum Reprod 1987; 8: 665–671.Google Scholar
  2. 2.
    Sokol RZ. Medical endocrine therapy of male factor infertility. In: Overstreet JW, ed. Infertility Reproductive Medicine Clinics of North America. Philadelphia: W.B. Saunders, Harcourt, Brace, Jovanovich; 1992; 3: 389–397.Google Scholar
  3. 3.
    Nagy Z, Liu J, Cecile J, et al. Using ejaculated, fresh, and frozen-thawed epididymal and testicular spermatozoa gives rise to comparable results after intracytoplasmic sperm injection. Fertil Steril 1995; 63: 808–815.PubMedGoogle Scholar
  4. 4.
    Sokol RZ, Palacios A, Campfield LA, et al. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982; 37: 425–430.PubMedGoogle Scholar
  5. 5.
    Findlay JAC, Place VA, Snyder PJ. Transdermal delivery of testosterone. J Clin Endocrinol Metab 1987; 64: 266–268.PubMedCrossRefGoogle Scholar
  6. 6.
    Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems. JAMA 1989; 261: 2525–2530.PubMedCrossRefGoogle Scholar
  7. 7.
    Molitch ME, Etton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60: 698–705.PubMedCrossRefGoogle Scholar
  8. 8.
    Sherins RJ, Howards SS II. Male infertility. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, eds. Campbell’s Urology. Philadelphia: W.B. Saunders; 1986: 640–697.Google Scholar
  9. 9.
    Ley SB, Leonard JM. Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropic and human menopausal gonadotropin, including prior endogenous androgens. J Clin Endocrinol Metab 1985; 61: 746–752.PubMedCrossRefGoogle Scholar
  10. 10.
    Hamman M, Berg AA. Long-term androgen replacement therapy does not preclude gonadotropin-induced improvement of spermatogenesis Scand J Urol Nephrol 1990; 24: 17–19.CrossRefGoogle Scholar
  11. 11.
    Sokol RZ, McClure RD, Peterson M, et al. Gonaodotropin therapy failure secondary to hCG induced antibodies. J Clin Endocrinol Metab 1981; 52: 929–933.PubMedCrossRefGoogle Scholar
  12. 12.
    Hoffman AR, Crowley WF. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982; 307: 1237–1241.PubMedCrossRefGoogle Scholar
  13. 13.
    Skarin G, Nillius SJ, Wibell I. Chronic pulsatile low dose GnRH therapy for induction of testosterone production and spermatogenesis in a man with secondary hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1982; 55: 723–726.PubMedCrossRefGoogle Scholar
  14. 14.
    Donald RA, Wheeler M, Sonksen PH, et al. Hypogonadotropic hypogonadism resistant to hCG and responsive to GnRH: report of a case. Clin Endocrinol 1983; 18: 385–389.CrossRefGoogle Scholar
  15. 15.
    Shoham Z, Conway CS, Ostergaard H, et al. Co-treatment with growth hormone for induction of spermatogenesis in patients with hypogonadotropic hypogonadism. Fertil Steril 1992; 57: 1044–1051.PubMedGoogle Scholar
  16. 16.
    Steinberger A. Clinical assessment of treatment results in male infertility. In: Santen RJ, Swerdloff RS, eds. Male Reproductive Dysfunction. New York: Marcel Dekker; 1986: 373–386.Google Scholar
  17. 17.
    Keough EJ, Burger HG, DeKretser DM, et al. Non-surgical management of male infertility. In: Hafez ESP, ed. Human Semen and Fertility Regulation in Men. St. Louis: C.V. Mosby; 1976: 452–463.Google Scholar
  18. 18.
    Gerris J, Comhaire F, Hellemans P, et al. Placebo-controlled trial of high-dose mesterolone treatment of idiopathic male infertility. Fertil Steril 1991; 55: 603–607.PubMedGoogle Scholar
  19. 19.
    Comhaire FH. Treatment of idiopathic testicular failure with high-dose testosterone undecanoate: a double-blind pilot study. Fertil Steril 1990; 54: 689–693.PubMedGoogle Scholar
  20. 20.
    Rosenberg E. Medical treatment of male infertility. Andrologia 1976; 8 (suppl 1): 95–107.Google Scholar
  21. 21.
    Lunenfeld B, Mor A, Mani M. Treatment of male infertility I. Human gonadotropins. Fertil Steril 1967; 18: 581–592.PubMedGoogle Scholar
  22. 22.
    Acosta AA, Khalifa E, Oehninger S. Pure human follicle stimulating hormone has a role in the treatment of severe male infertility by assisted reproduction: Norfolk’s total experience. Hum Reprod 1992; 7: 1067–1072.PubMedGoogle Scholar
  23. 23.
    Bartov Z, Eltes F, Lunenfeld E, et al. Sperm quality of subfertile males before and after treatment with follicle stimulating hormone. Fertil Steril 1994; 61: 727–734.Google Scholar
  24. 24.
    Crottaz B, Senn RF, Germond M, et al. Stimulating hormone bioactivity in idiopathic normogonadotropic oligoasthenozoospermia: double-blind trial with GnRH. Fertil Steril 1992; 57: 1034–1043.PubMedGoogle Scholar
  25. 25.
    Adashi EY. Clomiphene citrate. Mechanism(s) and site(s) of action: a hypothesis revisited. Fertil Steril 1985; 42: 331–344.Google Scholar
  26. 26.
    Weiland RG, Anasar AH, Klein DE, et al. Idiopathic oligospermia: control observations and response to cis-clomiphene. Fertility Steril 1972; 23: 471–474.Google Scholar
  27. 27.
    Mascala A, Delitala G, Alagna S, et al. Effect of clomiphene citrate on plasma levels of immunoreactive luteinizing hormone-releasing hormone, gonadotropin, and testosterone in normal subjects and in patients with idiopathic oligospermia. Fertil Steril 1978; 29: 424–427.Google Scholar
  28. 28.
    Foss GL, Tindal VR, Birkett JP. The treatment of subfertile men with clomiphene citrate. J Reprod Fertil 1973; 37: 167–170.Google Scholar
  29. 29.
    Wang C, Chan CW, Wong KK, et al. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril 1983; 40: 358–365.PubMedGoogle Scholar
  30. 30.
    Micic S, Dotlic M. Evaluation of sperm parameters in clinical trial with clomiphene citrate of oligospermic men. J Urol 1985; 133: 221–222.PubMedGoogle Scholar
  31. 31.
    Sokol RZ, Steiner BS, Bustillo M, et al. A controlled comparison of the efficacy of clomiphene citrate in male infertility. Fertil Steril 1988; 49: 865–870.PubMedGoogle Scholar
  32. 32.
    World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction Annual Technical Report 1990. Geneva: WHO; 1991: 146–147.Google Scholar
  33. 33.
    AinMelk Y, Belisle S, Caimel M, et al. Tamoxifen citrate therapy in male infertility. Fertil Steril 1987; 48: 113–117.PubMedGoogle Scholar
  34. 34.
    Buvat J, Ardaens K, Lemairc A, et al. Increased sperm count in 25 cases of idiopathic normogonadotropic oligospermia following treatment with tamoxifen. Fertil Steril 1983; 39: 700–703.PubMedGoogle Scholar
  35. 35.
    Comhaire FH. Treatment of oligospermia with tamoxifen. Int J Fertil 1976; 21: 232–238.Google Scholar
  36. 36.
    Comhaire FH. Tamoxifen. In: Bain J, Schill WB, Schwarzstein L, eds. Treatment of Male Infertility. New York: Springer-Verlag; 1982: 45.CrossRefGoogle Scholar
  37. 37.
    Vermeulen A, Comhaire F. Hormonal effects of an antiestrogen, tamoxifen, in normal andoligospermic men. Fertil Steril 1978; 29: 320–327.PubMedGoogle Scholar
  38. 38.
    Willis KJ, London DR, Bevis MA, et al. Hor monal effects of tamoxifen in oligospermic men. J Endocrinol 1977; 73: 171–178.PubMedCrossRefGoogle Scholar
  39. 39.
    Vigersky RA, Glass AR. Effects of delta-1-testolactone on the pituitary-testicular axis in oligospermic men. J Clin Endocrinol Metab 1981; 52: 897–902.PubMedCrossRefGoogle Scholar
  40. 40.
    Clark RV, Sherins RJ. Clinical trail of testolactone for treatment of idiopathic male in fertility. J Androl 1989; 10: 240–247.PubMedGoogle Scholar
  41. 41.
    Haas GG. Evaluation of sperm antibodies in autoimmunity in the infertile male. In: Santen RJ, Swerdloff RS, eds. Male Reproductive Dys-function. New York: Marcel Dekker; 1986: 439–456Google Scholar
  42. 42.
    Haas GG Jr, Manganiello P. A double-blind, placebo-controlled study of the use of methyl-prednisolone in infertile men with sperm-associated immunoglubulins. Fertil Steril 1987; 47: 295–301.PubMedGoogle Scholar
  43. 43.
    Hendry WF, Hughes L, Scammell G, et al.Comparison of prednisolone and placebo in subfertile men with antibodies to spermatozoa. Lancet 1990; 335: 85–88.PubMedCrossRefGoogle Scholar
  44. 44.
    Hendry WF. Bilateral aseptic necrosis of femoral heads following intermittent high-dose ste-roid therapy (letter). Fertil Steril 1982; 38: 120PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Rebecca Z. Sokol

There are no affiliations available

Personalised recommendations